Abstract:Abnormal vascular smooth muscle cell (SMC) activation is associated with various vascular disorders such as atherosclerosis, in-stent restenosis, vein graft disease, and transplantation-associated vasculopathy. Vinpocetine, a derivative of the alkaloid vincamine, has long been used as a cerebral blood flow enhancer for treating cognitive impairment. However, its role in pathological vascular remodeling remains unexplored. Herein, we show that systemic administration of vinpocetine significantly reduced neointimal formation in carotid arteries after ligation injury. Vinpocetine also markedly decreased spontaneous remodeling of human saphenous vein explants in ex vivo culture. In cultured SMCs, vinpocetine dose-dependently suppressed cell proliferation and caused G1-phase cell cycle arrest, which is associated with a decrease in cyclin D1 and an increase in p27Kip1 levels. In addition, vinpocetine dose-dependently inhibited platelet-derived growth factor (PDGF)-stimulated SMC migration as determined by the two-dimensional migration assays and three-dimensional aortic medial explant invasive assay. Moreover, vinpocetine significantly reduced PDGF-induced type I collagen and fibronectin expression. It is noteworthy that PDGF-stimulated phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), but not protein kinase B, was specifically inhibited by vinpocetine. Vinpocetine powerfully attenuated intracellular reactive oxidative species (ROS) production, which largely mediates the inhibitory effects of vinpocetine on ERK1/2 activation and SMC growth. Taken together, our results reveal a novel function of vinpocetine in attenuating neointimal hyperplasia and pathological vascular remodeling, at least partially through suppressing ROS production and ERK1/2 activation in SMCs. Given the safety profile of vinpocetine, this study provides insight into the therapeutic potential of vinpocetine in proliferative vascular disorders.

Synthesis and Biological Evaluation of Vinpocetine Derivatives

Synthesis and Activity Evaluation of Vinpocetine-Derived Indole Alkaloids

Synthesis and pharmacological activity of vinpocetine derivatives

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Synthesis and biological evaluation of novel hybrid chalcone derivatives as vasorelaxant agents.

Design, synthesis and biological evaluation of dehydroabietic acid derivative as potent vasodilatory agents

Synthesis and pharmacological profile of non-peptide vasopressin antagonists

Synthesis and Biological Evaluation of Isosteviol Derivatives As FXa Inhibitors.

Synthesis and Biological Evaluation of Panaxatriol Derivatives Against Myocardial Ischemia/reperfusion Injury in the Rat

Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration

Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket

Design, synthesis, and biological evaluation of prenylated chalcones as vasorelaxant agents.

[Synthesis and Vasorelaxation Action of Flavonoids].

Synthesis and Biological Evaluation of Flavonoids As Vasorelaxant Agents

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Synthesis, biological evaluation of prenylflavonoids as vasorelaxant and neuroprotective agents.

Design, Synthesis and Biological Evaluation of Novel Tetrahydroisoquinoline Derivatives As Potential PDE4 Inhibitors.

Identification of SVM-based Classification Model, Synthesis and Evaluation of Prenylated Flavonoids As Vasorelaxant Agents

Syntheses and evaluation of daphnetin derivatives as novel G protein-coupled receptor inhibitors and activators

Synthesis and Biological Evaluation of Glycyrrhetic Acid Derivatives As Potential VEGFR2 Inhibitors

Preparation and Preliminary Structure–Activity Relationship Studies of Schwarzinicine A Analogs as Vasorelaxant Agents